Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency

American Journal of Kidney Diseases

Volumn 39, Issue 1, 2002, Pages 67-75

  Samuelsson, Ola ^a   Attman, Per Ola ^a   Knight Gibson, Carolyn ^a   Mulec, Henrik ^a   Weiss, Lars ^a   Alaupovic, Petar ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apolipoproteins (apo); Chronic renal insufficiency; Fluvastatin; Lipids; Lipoproteins (Lp)

Indexed keywords

APOLIPOPROTEIN B; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BODY SURFACE; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0036142709     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2002.29883     Document Type: Article

References (57)

1. Lipoprotein metabolism and renal failure
2. Lipoprotein abnormalities without hyperlipidemia in moderate renal insufficiency
3. Increased concentrations of apoB-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure
4. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of apoA-and apoB-containing lipoprotein families
5. Triglyceride-rich and cholesterol-rich lipoproteins have a differential effect on mild to moderate/severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
6. Atherogenicity of triglyceride-rich lipoproteins
7. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal disease
8. Hypertriglyceridemia and hyperuricaemia are risk factors for progression of IgA nephropathy
9. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency
10. Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis
11. The effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency. A controlled study in human chronic renal disease
12. Lipidlowering therapy in patients with renal disease
13. Ongoing clinical trials of lipid reduction therapy in patients with renal disease
14. Fibrates and statins in the treatment of hyperlipidaemia; An appraisal of their efficacy and safety
15. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition
16. A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition
17. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia
18. Effects of lovastatin on apoA- and apoB-containing lipoprotein families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS)
19. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels
20. Effect of fluvastatin on intermediate-density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia
21. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a)
22. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition
23. Fluvastatin: A review of its use in lipid disorders
24. Long term efficacy with fluvastatin as monotherapy and combined with cholestyramine (a 156-week multicenter study)
25. Efficacy and tolerability of fluvastatin and simvastatin in hypercholesterolaemic patients. A double-blind, randomised, parallel-group comparison
26. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
27. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy
28. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers
29. Studies on the mechanism of hypertriglyceridemia in Tangier disease. Determination of plasma lipolytic activities, kl values and apolipoprotein composition of the major lipoprotein density classes
30. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge
31. Quantitative determination of human plasma apolipoproteins by electroimmunoassays
32. The lipoprotein family concept and its clinical significance
33. Differential immunoassay of human Lp-AI lipoprotein particles on ready to-use-plates
34. Quantification of two different types of lipoprotein A-I containing lipoprotein particles in plasma by enzyme-linked differential-antibody immunosorbers assay
35. 3H cholesteryl linoleyl ether-labeled Lp(a) in different rat organs
36. Determination of glomerular filtration rate in advanced renal insufficiency
37. Effect of statins on risk of coronary heart disease. A meta-analysis of randomized trials
38. Clinical lipidology at the end of the millenium
39. The evolving role of statins in the management of atherosclerosis
40. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency
41. Efficiency of 1-year treatment with fluvastatin in hyperlipidemic patients with nephrotic syndrome
42. Cardiovascular disease in patients with chronic renal failure
43. Lipids and the progression of renal disease
44. The emergence of triglycerides as a significant independent risk factor in coronary artery disease
45. Triglyceride. The forgotten risk factor
46. Plasma triglycerides and the clinician: Time for reassessment
47. Lipoprotein heterogeneity and apolipoprotein B metabolism
48. What can we learn about dense low lipoprotein and lipoprotein particles from clinical trials?
49. Atherosclerotic prevention for the next decade: Risk assessment beyond LDL cholesterol
50. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled trial
51. Lipids and the kidney
52. The role of lipids in renal disease
53. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease
54. Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis
55. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis
56. Effect of lipid reduction on the progression of renal disease: A meta-analysis